Overexpression of mitochondrial transcription factor A ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction

Masaki Ikeuchi, Hidenori Matsusaka, Dongchon Kang, Shouji Matsushima, Tomomi Ide, Toru Kubota, Toshiyuki Fujiwara, Naotaka Hamasaki, Akira Takeshita, Kenji Sunagawa, Hiroyuki Tsutsui

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Background - Mitochondrial DNA (mtDNA) copy number is decreased not only in mtDNA-mutation diseases but also in a wide variety of acquired degenerative and ischemic diseases. Mitochondrial transcription factor A (TFAM) is essential for mtDNA transcription and replication. Myocardial mtDNA copy number and TFAM expression both decreased in cardiac failure. However, the functional significance of TFAM has not been established in this disease state. Methods and Results - We have now addressed this question by creating transgenic (Tg) mice that overexpress human TFAM gene and examined whether TFAM could protect the heart from mtDNA deficiencies and attenuate left ventricular (LV) remodeling and failure after myocardial infarction (MI) created by ligating the left coronary artery. TFAM overexpression could ameliorate the decrease in mtDNA copy number and mitochondrial complex enzyme activities in post-MI hearts. Survival rate during 4 weeks of MI was significantly higher in Tg-MI than in wild-type (WT) littermates (WT-MI), although infarct size was comparable. LV cavity dilatation and dysfunction were significantly attenuated in Tg-MI. LV end-diastolic pressure was increased in WT-MI, and it was also reduced in Tg-MI. Improvement of LV function in Tg-MI was accompanied by a decrease in myocyte hypertrophy, apoptosis, and interstitial fibrosis as well as oxidative stress in the noninfarcted LV. Conclusions - Overexpression of TFAM inhibited LV remodeling after MI. TFAM may provide a novel therapeutic strategy of cardiac failure.

Original languageEnglish
Pages (from-to)683-690
Number of pages8
JournalCirculation
Volume112
Issue number5
DOIs
Publication statusPublished - Aug 2 2005

Fingerprint

Heart Failure
Myocardial Infarction
Mitochondrial DNA
Ventricular Remodeling
mitochondrial transcription factor A
DNA Replication
Left Ventricular Function
Muscle Cells
Hypertrophy
Transgenic Mice
Dilatation
Coronary Vessels
Oxidative Stress
Fibrosis
Apoptosis
Blood Pressure
Mutation
Enzymes
Genes

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Overexpression of mitochondrial transcription factor A ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. / Ikeuchi, Masaki; Matsusaka, Hidenori; Kang, Dongchon; Matsushima, Shouji; Ide, Tomomi; Kubota, Toru; Fujiwara, Toshiyuki; Hamasaki, Naotaka; Takeshita, Akira; Sunagawa, Kenji; Tsutsui, Hiroyuki.

In: Circulation, Vol. 112, No. 5, 02.08.2005, p. 683-690.

Research output: Contribution to journalArticle

Ikeuchi, Masaki ; Matsusaka, Hidenori ; Kang, Dongchon ; Matsushima, Shouji ; Ide, Tomomi ; Kubota, Toru ; Fujiwara, Toshiyuki ; Hamasaki, Naotaka ; Takeshita, Akira ; Sunagawa, Kenji ; Tsutsui, Hiroyuki. / Overexpression of mitochondrial transcription factor A ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. In: Circulation. 2005 ; Vol. 112, No. 5. pp. 683-690.
@article{4bccd5b78a094e969c108ebfc9679a7e,
title = "Overexpression of mitochondrial transcription factor A ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction",
abstract = "Background - Mitochondrial DNA (mtDNA) copy number is decreased not only in mtDNA-mutation diseases but also in a wide variety of acquired degenerative and ischemic diseases. Mitochondrial transcription factor A (TFAM) is essential for mtDNA transcription and replication. Myocardial mtDNA copy number and TFAM expression both decreased in cardiac failure. However, the functional significance of TFAM has not been established in this disease state. Methods and Results - We have now addressed this question by creating transgenic (Tg) mice that overexpress human TFAM gene and examined whether TFAM could protect the heart from mtDNA deficiencies and attenuate left ventricular (LV) remodeling and failure after myocardial infarction (MI) created by ligating the left coronary artery. TFAM overexpression could ameliorate the decrease in mtDNA copy number and mitochondrial complex enzyme activities in post-MI hearts. Survival rate during 4 weeks of MI was significantly higher in Tg-MI than in wild-type (WT) littermates (WT-MI), although infarct size was comparable. LV cavity dilatation and dysfunction were significantly attenuated in Tg-MI. LV end-diastolic pressure was increased in WT-MI, and it was also reduced in Tg-MI. Improvement of LV function in Tg-MI was accompanied by a decrease in myocyte hypertrophy, apoptosis, and interstitial fibrosis as well as oxidative stress in the noninfarcted LV. Conclusions - Overexpression of TFAM inhibited LV remodeling after MI. TFAM may provide a novel therapeutic strategy of cardiac failure.",
author = "Masaki Ikeuchi and Hidenori Matsusaka and Dongchon Kang and Shouji Matsushima and Tomomi Ide and Toru Kubota and Toshiyuki Fujiwara and Naotaka Hamasaki and Akira Takeshita and Kenji Sunagawa and Hiroyuki Tsutsui",
year = "2005",
month = "8",
day = "2",
doi = "10.1161/CIRCULATIONAHA.104.524835",
language = "English",
volume = "112",
pages = "683--690",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Overexpression of mitochondrial transcription factor A ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction

AU - Ikeuchi, Masaki

AU - Matsusaka, Hidenori

AU - Kang, Dongchon

AU - Matsushima, Shouji

AU - Ide, Tomomi

AU - Kubota, Toru

AU - Fujiwara, Toshiyuki

AU - Hamasaki, Naotaka

AU - Takeshita, Akira

AU - Sunagawa, Kenji

AU - Tsutsui, Hiroyuki

PY - 2005/8/2

Y1 - 2005/8/2

N2 - Background - Mitochondrial DNA (mtDNA) copy number is decreased not only in mtDNA-mutation diseases but also in a wide variety of acquired degenerative and ischemic diseases. Mitochondrial transcription factor A (TFAM) is essential for mtDNA transcription and replication. Myocardial mtDNA copy number and TFAM expression both decreased in cardiac failure. However, the functional significance of TFAM has not been established in this disease state. Methods and Results - We have now addressed this question by creating transgenic (Tg) mice that overexpress human TFAM gene and examined whether TFAM could protect the heart from mtDNA deficiencies and attenuate left ventricular (LV) remodeling and failure after myocardial infarction (MI) created by ligating the left coronary artery. TFAM overexpression could ameliorate the decrease in mtDNA copy number and mitochondrial complex enzyme activities in post-MI hearts. Survival rate during 4 weeks of MI was significantly higher in Tg-MI than in wild-type (WT) littermates (WT-MI), although infarct size was comparable. LV cavity dilatation and dysfunction were significantly attenuated in Tg-MI. LV end-diastolic pressure was increased in WT-MI, and it was also reduced in Tg-MI. Improvement of LV function in Tg-MI was accompanied by a decrease in myocyte hypertrophy, apoptosis, and interstitial fibrosis as well as oxidative stress in the noninfarcted LV. Conclusions - Overexpression of TFAM inhibited LV remodeling after MI. TFAM may provide a novel therapeutic strategy of cardiac failure.

AB - Background - Mitochondrial DNA (mtDNA) copy number is decreased not only in mtDNA-mutation diseases but also in a wide variety of acquired degenerative and ischemic diseases. Mitochondrial transcription factor A (TFAM) is essential for mtDNA transcription and replication. Myocardial mtDNA copy number and TFAM expression both decreased in cardiac failure. However, the functional significance of TFAM has not been established in this disease state. Methods and Results - We have now addressed this question by creating transgenic (Tg) mice that overexpress human TFAM gene and examined whether TFAM could protect the heart from mtDNA deficiencies and attenuate left ventricular (LV) remodeling and failure after myocardial infarction (MI) created by ligating the left coronary artery. TFAM overexpression could ameliorate the decrease in mtDNA copy number and mitochondrial complex enzyme activities in post-MI hearts. Survival rate during 4 weeks of MI was significantly higher in Tg-MI than in wild-type (WT) littermates (WT-MI), although infarct size was comparable. LV cavity dilatation and dysfunction were significantly attenuated in Tg-MI. LV end-diastolic pressure was increased in WT-MI, and it was also reduced in Tg-MI. Improvement of LV function in Tg-MI was accompanied by a decrease in myocyte hypertrophy, apoptosis, and interstitial fibrosis as well as oxidative stress in the noninfarcted LV. Conclusions - Overexpression of TFAM inhibited LV remodeling after MI. TFAM may provide a novel therapeutic strategy of cardiac failure.

UR - http://www.scopus.com/inward/record.url?scp=23244452012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23244452012&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.104.524835

DO - 10.1161/CIRCULATIONAHA.104.524835

M3 - Article

C2 - 16043643

AN - SCOPUS:23244452012

VL - 112

SP - 683

EP - 690

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5

ER -